Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC

Open source

DOI: 10.1016/j.lungcan.2026.109302
Published: 2026 Mar
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109302,
  title = {Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.},
  author = {Zhou C and Tang KJ and Liu B and Kim SW and Kitazono S and Ono A and Thiagarajan M and Hung JY and Boyer M and Çİl T and Yao Y and Nagarkar R and Xie J and Bhattacharya A and Wortman-Vayn H and Baig M and Agrawal T and Lorenzini P and Lee SH and Cho BC},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109302},
  url = {https://doi.org/10.1016/j.lungcan.2026.109302}
}

RIS

TY  - JOUR
TI  - Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.
AU  - Zhou C
AU  - Tang KJ
AU  - Liu B
AU  - Kim SW
AU  - Kitazono S
AU  - Ono A
AU  - Thiagarajan M
AU  - Hung JY
AU  - Boyer M
AU  - Çİl T
AU  - Yao Y
AU  - Nagarkar R
AU  - Xie J
AU  - Bhattacharya A
AU  - Wortman-Vayn H
AU  - Baig M
AU  - Agrawal T
AU  - Lorenzini P
AU  - Lee SH
AU  - Cho BC
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109302
UR  - https://doi.org/10.1016/j.lungcan.2026.109302
ER  -

APA

C, Z., KJ, T., B, L., SW, K., S, K., A, O., M, T., JY, H., M, B., T, Ç., Y, Y., R, N., J, X., A, B., H, W., M, B., T, A., P, L., SH, L., & BC, C. (2026). Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109302

Source records

pubmed · retrieved 2026-09-26T09:16:45.849Z
europe-pmc · retrieved 2026-09-26T09:16:45.869Z